Effect of an anticancer agent, vinblastine, on mouse skin.
The effect of vinblastine (VLB), an anticancer agent which has recently been shown to have Epstein-Barr virus (EBV)-activating potency, on CD-1 mouse skin was investigated. A single topical application of either 15 or 100 micrograms of VLB induced epidermal hyperplasia. Twice weekly applications of these doses of VLB either for 29 weeks after a 7,12-dimethylbenz(a)anthracene (DMBA) initiation (one-stage promotion) or for 27 weeks after DMBA initiation and a limited treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA) (two-stage promotion) failed to show any significant tumor-promoting activity at 30 weeks. The problem of EBV activation and its relationship to tumor promotion should await more definitive studies.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology; D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000187:drug effects; D005260:Female; D004854:Herpesvirus 4, Human; D006965:Hyperplasia / Q000139:chemically induced; D051379:Mice; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014747:Vinblastine / Q000633:toxicity*; D014775:Virus Activation / Q000187:drug effects
D015127:9,10-Dimethyl-1,2-benzanthracene; D014747:Vinblastine; D013755:Tetradecanoylphorbol Acetate